Description

Vonoprazan Tablets 20mg – VOQOZON 20 TABLETS:

Description
It is composition of Vonoprazan Tablets 20mg – VOQOZON 20 is a potassium-competitive acid blocker (PCAB) that inhibits H+, K+-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. Unlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations. Furthermore, vonoprazan is 400-times more potent than the proton-pump inhibitor lansoprazole, due to its ability to accumulate in the gastric corpus mucosa, specifically in the parietal cells.

Key Points:
With Resistant patients: Unlike PPIs, it irreversibly binds with the proton pump [H+, K+-ATPase] to manage hyperacidity, thus effective in PPI-resistant patients.
Faster actions: Up to 400 times more potent than PPIs, longer and rapid onset of action as compared to PPI-like lansoprazole.
Fewer side effects: Less chances of drug interactions and helps to lower the PPI-associated side effects.

Targeted Specialties:
Gastrointestinal
General Physicians
Internal Medicine Specialists

Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.